Mubadala Bio has announced Dr. Essam Mohamed as its new Chief Executive Officer (CEO), effective September 22, 2025. With over 30 years of experience in the pharmaceutical industry, Dr. Mohamed has held senior leadership roles in both regional and global organizations. He brings expertise across manufacturing, business operations, and strategic growth, having successfully led major transformations and regulatory enhancements in the sector.
The executive leadership team also includes Hamad Husein Al Marzooqi as Deputy CEO, Atif Azeem as Chief Financial Officer, and Khalid Abdallah Al-Kaf as General Manager of Pharma Logistics. Together, they aim to strengthen Mubadala Bio’s operational excellence and drive innovation across the life sciences sector. The team’s experience spans global markets including the UAE, Russia, Brazil, and the UK, with extensive expertise in finance, investments, and logistics.
Mubadala Bio’s leadership appointments reflect the company’s vision to enhance national drug security, expand access to high-quality therapeutics, and position Abu Dhabi as a global biopharma hub. These initiatives support the UAE’s Centennial 2071 vision, focusing on integrated biopharma and pharma logistics to foster innovation, economic diversification, and a knowledge-based economy.
